Sign in Subscribe
Cancer

Genprex Secures Patents for Reqorsa in Combination with Immune Checkpoint Inhibitors

Strategic Insights

— 1 min read

Genprex, a clinical-stage gene therapy company, has been granted patents for its lead drug candidate, Reqorsa, in combination with PD-L1 and PD-1 antibodies by the U.S. Patent and Trademark Office and the European Patent Office. These patents will expire in 2037 at the earliest, providing Genprex with intellectual property protection for its oncology program. The company is pursuing additional patent applications in various countries, including Europe, Canada, and Asia.

Key Takeaways:

  • Genprex has been granted patents for the use of Reqorsa in combination with PD-L1 antibodies in Korea and PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.
  • The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering the use of Reqorsa with PD-L1 antibodies, and the European Patent Office has issued a Notice of Allowance for a patent covering the use of Reqorsa with PD-1 antibodies.
  • Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel to further strengthen its intellectual property estate.
  • Reqorsa is being developed for use in combination with immune checkpoint inhibitors, such as Tecentriq and PD-1 antibodies, as part of the Acclaim-3 clinical trial.
  • Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex, stated that the new patents will provide a "fortress of intellectual property protection" around Genprex's oncology program.

Statistics:

  • 2037: Earliest expiration date for the granted patents.
  • 10: Number of countries where Genprex has been granted patents for Reqorsa in combination with PD-1 antibodies.
  • 5: Number of countries where Genprex is pursuing additional patent applications for Reqorsa.
  • 3: Number of clinical trials mentioned (Acclaim-1, Acclaim-2, and Acclaim-3) where Reqorsa is being developed for use in combination with immune checkpoint inhibitors.

Sources:

  • Genprex, Inc. press release (https://www.genprex.com/news-releases/genprex-announces-receipt-of-notice-of-allowance-from-the-us-patent-and-trademark-office-for-patent-coverage-of-reqorsa-in-combination-with-pd-l1-antibodies)

Read more